{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:33:45Z","timestamp":1791178425934,"version":"4.1.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8,24]]},"DOI":"10.1097\/qad.0b013e32832d7350","type":"journal-article","created":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T19:49:22Z","timestamp":1250192962000},"page":"1679-1688","source":"Crossref","is-referenced-by-count":214,"title":["Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis"],"prefix":"10.1097","volume":"23","author":[{"given":"Anthony M","family":"Mills","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dushyantha","family":"Jayaweera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiat","family":"Ruxrungtham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Cassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Marie","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassy","family":"Workman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Dierynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanitha","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carline Vanden","family":"Abeele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo","family":"Lavreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210130","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"R2-7-20210130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/QAI.0b013e3181359cfb","article-title":"Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3","volume":"46","author":"Molina","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R3-7-20210130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"R5-7-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/135965350801300101","article-title":"Darunavir: pharmacokinetics and drug interactions","volume":"13","author":"Back","year":"2008","journal-title":"Antivir Ther"},{"key":"R6-7-20210130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1310\/hct0906-418","article-title":"Pharmacokinetics, efficacy, and safety of darunavir\/ritonavir 800\/100 mg once-daily in treatment-na\u00efve and -experienced patients","volume":"9","author":"Boffito","year":"2008","journal-title":"HIV Clin Trials"},{"key":"R7-7-20210130","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","article-title":"TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates","volume":"49","author":"De Meyer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R8-7-20210130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1086\/426595","article-title":"Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors","volume":"40","author":"Maggiolo","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R9-7-20210130","first-page":"179","article-title":"Efficacy of once-daily darunavir\/ritonavir 800\/100mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir","volume":"49","author":"De Meyer","year":"2008","journal-title":"J AIDS"},{"key":"R10-7-20210130","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-na\u00efve HIV-1-infected patients at week 48","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"R12-7-20210130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"R13-7-20210130","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00002030-200201250-00017","article-title":"Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome","volume":"16","author":"Walsh","year":"2002","journal-title":"AIDS"},{"key":"R14-7-20210130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","article-title":"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection","volume":"133","author":"Paterson","year":"2000","journal-title":"Ann Intern Med"},{"key":"R17-7-20210130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jmv.21034","article-title":"Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs","volume":"80","author":"Perno","year":"2008","journal-title":"J Med Virol"},{"key":"R18-7-20210130","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.2174\/1381612043382404","article-title":"Drug resistance, virus fitness and HIV-1 mutagenesis","volume":"10","author":"Chen","year":"2004","journal-title":"Curr Pharm Des"},{"key":"R19-7-20210130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/00002030-199905070-00008","article-title":"The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs","volume":"13","author":"Murray","year":"1999","journal-title":"AIDS"},{"key":"R20-7-20210130","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJM199602153340703","article-title":"Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS","volume":"334","author":"O'Brien","year":"1996","journal-title":"N Engl J Med"},{"key":"R21-7-20210130","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/aid.2007.0107","article-title":"A lopinavir\/ritonavir-based once-daily regimen results in better compliance and is noninferior to a twice-daily regimen through 96 weeks","volume":"23","author":"Molina","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R24-7-20210130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"R25-7-20210130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1468-1293.2004.00193.x","article-title":"The high cost of medical care for patients who present late (CD4 <200 cells\/ml) with HIV infection","volume":"5","author":"Krentz","year":"2004","journal-title":"HIV Med"},{"key":"R26-7-20210130","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1097\/00002030-200411050-00006","article-title":"Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy","volume":"18","author":"Sabin","year":"2004","journal-title":"AIDS"},{"key":"R27-7-20210130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00126334-200302010-00005","article-title":"Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection","volume":"32","author":"Klein","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R28-7-20210130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/01.qai.0000243114.37035.de","article-title":"Late diagnosis of HIV infection trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS","volume":"43","author":"Schwarcz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R31-7-20210130","first-page":"367","article-title":"Gemini: a noninferiority study of saquinavir\/ritonavir versus lopinavir\/ritonavir as initial HIV-1 therapy in adults","volume":"50","author":"Walmsley","year":"2009","journal-title":"J AIDS"},{"key":"R32-7-20210130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/380509","article-title":"Incidence of resistance in a double-blind study comparing lopinavir\/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine","volume":"189","author":"Kempf","year":"2004","journal-title":"J Infect Dis"},{"key":"R33-7-20210130","first-page":"4","article-title":"Lack of major resistance mutations in HIV-1 protease at failure of boosted protease inhibitor-based first-line antiretroviral treatment","volume":"2","author":"Zazzi","year":"2007","journal-title":"Rev Antivir Ther"},{"key":"R34-7-20210130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","article-title":"Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1","volume":"21","author":"Katlama","year":"2007","journal-title":"AIDS"},{"key":"R35-7-20210130","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/QAD.0b013e3280b07b47","article-title":"Week 24 efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients","volume":"21","author":"Haubrich","year":"2007","journal-title":"AIDS"},{"key":"R36-7-20210130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/QAI.0b013e31803133c5","article-title":"The tablet formulation of lopinavir\/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect","volume":"44","author":"Klein","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R37-7-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/hct1001-1","article-title":"Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels","volume":"10","author":"Hill","year":"2009","journal-title":"HIV Clin Trials"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002030-200908240-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T09:46:42Z","timestamp":1685094402000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-200908240-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,24]]},"references-count":29,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32832d7350","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8,24]]}}}